Gastroenterology Podcast April 2014: Anti-Tumor Necrosis Factor Monotherapy vs Combination Therapy for Inflammatory Bowel Disease
An editorial in the April issue of Gastroenterology compares anti-tumor necrosis factor monotherapy with combination therapy for inflammatory bowel disease. A related article in the same issue also compares increased risk of malignancy with adalimumab combination therapy to monotherapy for Crohn's disease Dr. Kuemmerle speaks with editorial co-author Dr. Corey A. Siegel of Dartmouth-Hitchcock Medical Center; Plus, a rundown of top stories from this month's issue of GI and Hepatology News.
Bressler B, Siegel CA. Beware of the Swinging Pendulum: Anti-Tumor Necrosis Factor Monotherapy vs Combination Therapy for Inflammatory Bowel Disease. Gastroenterology 2014; April; 146(4): 884-887
Osterman MT, Sandborn WJ, Colombel JF, et al. Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease. Gastroenterology 2014; April; 146(4): 941-949
Bitrate: 96 KBPS
Frequency: 44100 HZ